tiprankstipranks
Trending News
More News >

CR Sanjiu Reports Q1 2025 Financial Results with Strong Cash Flow

Story Highlights

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.

CR Sanjiu released its unaudited financial results for the first quarter of 2025, reporting a decline in revenue and net profit compared to the same period in 2024. Despite the drop in revenue and profit, the company experienced a significant increase in cash and cash equivalents, indicating strong cash flow management. The financial results highlight a substantial growth in total assets and liabilities, reflecting ongoing expansion efforts. Stakeholders are advised to exercise caution, as these figures are unaudited and may be subject to adjustments.

More about China Resources Pharmaceutical Group Ltd.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd, a subsidiary of China Resources Pharmaceutical Group Ltd, operates in the pharmaceutical industry. It is primarily involved in the production and distribution of medical and pharmaceutical products, with its shares listed on the Shenzhen Stock Exchange.

YTD Price Performance: -19.26%

Average Trading Volume: 1,550

Technical Sentiment Signal: Buy

Current Market Cap: €3.51B

See more data about 3320 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App